TRIBE-2: a phase III, randomized, open-label, strategy trial in unresectable metastatic colorectal cancer patients by the GONO group

BACKGROUND: Chemotherapy plus bevacizumab is a standard first-line treatment for unresectable metastatic colorectal cancer patients. Different chemotherapy backbones may be chosen, including one to three drugs, based on patients’ general conditions and comorbidities, treatments’ objectives, and dise...

Full description

Saved in:
Bibliographic Details
Published in:BMC Cancer
Main Authors: Cremolini, Chiara, Marmorino, Federica, Loupakis, Fotios, Masi, Gianluca, Antoniotti, Carlotta, Salvatore, Lisa, Schirripa, Marta, Boni, Luca, Zagonel, Vittorina, Lonardi, Sara, Aprile, Giuseppe, Tamburini, Emiliano, Ricci, Vincenzo, Ronzoni, Monica, Pietrantonio, Filippo, Valsuani, Chiara, Tomasello, Gianluca, Passardi, Alessandro, Allegrini, Giacomo, Di Donato, Samantha, Santini, Daniele, Falcone, Alfredo
Format: Artigo
Language:Inglês
Published: BioMed Central 2017
Subjects:
Study Protocol
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC5466800/
https://ncbi.nlm.nih.gov/pubmed/28599628
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-017-3360-z
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items